Scandinavian Cohort Study for Optimal Use of Portal Vein Embolization

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04182386

Enrollment

300

Registered

2019-12-02

Start date

2012-08-01

Completion date

2022-12-31

Last updated

2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Neoplasm

Brief summary

Several aspects on the use of portal vein embolization (PVE) are poorly studied and todays recommendations are based on low-grade evidence. In this Scandinavian multicenter cohort study we will study some of the controversial aspects on the use of PVE to try to provide clearer answers on its optimal use. Six tertiary university hospital hepatobiliary units in Sweden, Norway and Denmark participate and contribute with all PVE procedures performed at their units during the study period. We will then study several aspects PVE technique in relation to induced hypertrophy and surgical outcome.

Interventions

PROCEDUREPortal vein embolization

Selective preoperative portal vein embolization

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Right-sided PVE

Exclusion criteria

* Left-sided PVE

Design outcomes

Primary

Measure	Time frame	Description
Future liver remnant hypertrophy	Based on radiology around 4 weeks before and after intervention	Increase in future liver remnant, (%)

Secondary

Measure	Time frame	Description
Effect of segment 4 embolization on hypertrophy	Based on radiology around 4 weeks before and after intervention	Increase in future liver remnant (%) dependeing on if segment 4 is embolized or not.
Effect of hyperbilirubinemia on hypertrophy	Based on radiology around 4 weeks before and after intervention	Increase in future liver remnant (%) dependeing on the levels of bilirubin before portal vein embolization.
Effect of sarcopenia on hypertrophy	Based on radiology around 4 weeks before and after intervention	Increase in future liver remnant (%) dependeing on the level of sarcopenia before portal vein embolization.

Countries

Sweden

Contacts

Primary ContactErnesto Sparrelid, MD PhD

ernesto.sparrelid@ki.se+46-708-880787

Backup ContactStefan Gilg, MD PhD

stefan.gilg@ki.se+46-702-677722

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026